Pyruvate kinase M2 is a poor prognostic marker of and a therapeutic target in ovarian cancer.
Pyruvate kinase M2 (PKM2) regulates glycolysis and oxidative phosphorylation; however, the role of PKM2 in ovarian cancer remains largely unknown. We investigated whether ovarian cancer metabolism could provide insight into the development of therapeutic strategies. We performed immunohistochemical...
Main Authors: | , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2017-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC5533430?pdf=render |
id |
doaj-b196ecc647b24f52b7d8c46c927a6df7 |
---|---|
record_format |
Article |
spelling |
doaj-b196ecc647b24f52b7d8c46c927a6df72020-11-24T21:36:17ZengPublic Library of Science (PLoS)PLoS ONE1932-62032017-01-01127e018216610.1371/journal.pone.0182166Pyruvate kinase M2 is a poor prognostic marker of and a therapeutic target in ovarian cancer.Tai-Kuang ChaoTien-Shuo HuangYu-Ping LiaoRui-Lan HuangPo-Hsuan SuHueng-Yuan ShenHung-Cheng LaiYu-Chi WangPyruvate kinase M2 (PKM2) regulates glycolysis and oxidative phosphorylation; however, the role of PKM2 in ovarian cancer remains largely unknown. We investigated whether ovarian cancer metabolism could provide insight into the development of therapeutic strategies. We performed immunohistochemical staining for PKM2 on a tissue microarray for multivariate analysis. It revealed that patients exhibiting higher PKM2 expression were significantly associated with malignancy groups (p < 0.001) and pathogenesis models (p < 0.001), had poor progression-free survival rates (p = 0.01) as compared with patients exhibiting lower PKM2 levels, and yielded a hazard ratio of death of 2.02 (95% confidence interval: 0.70-5.85). In cell lines, PKM2 inhibitor significantly inhibited the glycolytic rate according to cellular glucose consumption (p < 0.001). We also utilized Seahorse assays to assess metabolism-related cell-specific factors and the impact of PKM2 inhibitors. Energy shifts as per Seahorse analysis showed attenuation of the extracellular acidification rate (p < 0.05) and no significant difference in oxygen-consumption rate in SKOV3 cells. Treatment with PKM2 inhibitor suppressed ovarian cancer growth and cell migration in vitro and inhibited tumor growth without significant toxicity in a xenograft study. PKM2 inhibition disturbed Warburg effects and inhibited ovarian cancer cell growth. Targeting PKM2 may constitute a promising therapy for patients with ovarian cancer, and clinical trials involving shikonin are warranted.http://europepmc.org/articles/PMC5533430?pdf=render |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Tai-Kuang Chao Tien-Shuo Huang Yu-Ping Liao Rui-Lan Huang Po-Hsuan Su Hueng-Yuan Shen Hung-Cheng Lai Yu-Chi Wang |
spellingShingle |
Tai-Kuang Chao Tien-Shuo Huang Yu-Ping Liao Rui-Lan Huang Po-Hsuan Su Hueng-Yuan Shen Hung-Cheng Lai Yu-Chi Wang Pyruvate kinase M2 is a poor prognostic marker of and a therapeutic target in ovarian cancer. PLoS ONE |
author_facet |
Tai-Kuang Chao Tien-Shuo Huang Yu-Ping Liao Rui-Lan Huang Po-Hsuan Su Hueng-Yuan Shen Hung-Cheng Lai Yu-Chi Wang |
author_sort |
Tai-Kuang Chao |
title |
Pyruvate kinase M2 is a poor prognostic marker of and a therapeutic target in ovarian cancer. |
title_short |
Pyruvate kinase M2 is a poor prognostic marker of and a therapeutic target in ovarian cancer. |
title_full |
Pyruvate kinase M2 is a poor prognostic marker of and a therapeutic target in ovarian cancer. |
title_fullStr |
Pyruvate kinase M2 is a poor prognostic marker of and a therapeutic target in ovarian cancer. |
title_full_unstemmed |
Pyruvate kinase M2 is a poor prognostic marker of and a therapeutic target in ovarian cancer. |
title_sort |
pyruvate kinase m2 is a poor prognostic marker of and a therapeutic target in ovarian cancer. |
publisher |
Public Library of Science (PLoS) |
series |
PLoS ONE |
issn |
1932-6203 |
publishDate |
2017-01-01 |
description |
Pyruvate kinase M2 (PKM2) regulates glycolysis and oxidative phosphorylation; however, the role of PKM2 in ovarian cancer remains largely unknown. We investigated whether ovarian cancer metabolism could provide insight into the development of therapeutic strategies. We performed immunohistochemical staining for PKM2 on a tissue microarray for multivariate analysis. It revealed that patients exhibiting higher PKM2 expression were significantly associated with malignancy groups (p < 0.001) and pathogenesis models (p < 0.001), had poor progression-free survival rates (p = 0.01) as compared with patients exhibiting lower PKM2 levels, and yielded a hazard ratio of death of 2.02 (95% confidence interval: 0.70-5.85). In cell lines, PKM2 inhibitor significantly inhibited the glycolytic rate according to cellular glucose consumption (p < 0.001). We also utilized Seahorse assays to assess metabolism-related cell-specific factors and the impact of PKM2 inhibitors. Energy shifts as per Seahorse analysis showed attenuation of the extracellular acidification rate (p < 0.05) and no significant difference in oxygen-consumption rate in SKOV3 cells. Treatment with PKM2 inhibitor suppressed ovarian cancer growth and cell migration in vitro and inhibited tumor growth without significant toxicity in a xenograft study. PKM2 inhibition disturbed Warburg effects and inhibited ovarian cancer cell growth. Targeting PKM2 may constitute a promising therapy for patients with ovarian cancer, and clinical trials involving shikonin are warranted. |
url |
http://europepmc.org/articles/PMC5533430?pdf=render |
work_keys_str_mv |
AT taikuangchao pyruvatekinasem2isapoorprognosticmarkerofandatherapeutictargetinovariancancer AT tienshuohuang pyruvatekinasem2isapoorprognosticmarkerofandatherapeutictargetinovariancancer AT yupingliao pyruvatekinasem2isapoorprognosticmarkerofandatherapeutictargetinovariancancer AT ruilanhuang pyruvatekinasem2isapoorprognosticmarkerofandatherapeutictargetinovariancancer AT pohsuansu pyruvatekinasem2isapoorprognosticmarkerofandatherapeutictargetinovariancancer AT huengyuanshen pyruvatekinasem2isapoorprognosticmarkerofandatherapeutictargetinovariancancer AT hungchenglai pyruvatekinasem2isapoorprognosticmarkerofandatherapeutictargetinovariancancer AT yuchiwang pyruvatekinasem2isapoorprognosticmarkerofandatherapeutictargetinovariancancer |
_version_ |
1725941879894179840 |